STEREOTACTIC RADIOSURGERY FOR RADIATION-INDUCED MENINGIOMAS

Neurosurgery ◽  
2009 ◽  
Vol 64 (3) ◽  
pp. 463-470 ◽  
Author(s):  
Douglas Kondziolka ◽  
Hideyuki Kano ◽  
Hilal Kanaan ◽  
Ricky Madhok ◽  
David Mathieu ◽  
...  
Keyword(s):  
Stereotactic Radiosurgery ◽  
Gamma Knife Radiosurgery ◽  
World Health ◽  
Morbidity Rate ◽  
Induced Tumors ◽  
Radiation Induced ◽  
Grade Ii ◽  
Health Organization ◽  
The Brain

Abstract OBJECTIVE Radiation-induced meningiomas of the brain are typically managed with surgical resection. Stereotactic radiosurgery (SRS) has become an important primary or adjuvant management for patients with intracranial meningiomas, but the value of this approach for radiation-induced tumors is unclear. METHODS This series consisted of 19 patients (mean age, 40 years) with 24 tumors. The patients met criteria for a radiation-induced meningioma and underwent gamma knife radiosurgery. Seven patients had undergone a previous resection. The World Health Organization tumor grades for those with prior histology were Grade I (n = 5) and Grade II (n = 2). The median tumor volume was 4.4 cm3. Radiosurgery was performed using a median margin dose of 13 Gy. RESULTS Serial imaging was evaluated in all patients at a median follow-up of 44 months. The control rate was 75% after primary radiosurgery. Delayed resection after radiosurgery was performed in 5 patients (26%) at an average of 39 months. The median latency between radiation therapy for original disease and SRS for radiation-induced meningiomas was 29.7 years (range, 7.3–59.0 years). The overall survival after SRS was 94.1% and 80.7% at 3 and 5 years, respectively. No patient developed a subsequent radiation-induced tumor. The overall morbidity rate was 5.3% (1 optic neuropathy). Asymptomatic peritumoral imaging changes compatible with an adverse radiation effect developed in 1 patient. CONCLUSION SRS provides satisfactory control rates either after resection or as an alternative to resection. Its role is most valuable for patients whose tumors affect critical neurological regions and who are poor candidates for resection.

Stereotactic radiation treatment for recurrent nonbenign meningiomas

2007 ◽  
Vol 106 (5) ◽  
pp. 846-854 ◽  
Author(s):  
Carlos A. Mattozo ◽  
Antonio A. F. De Salles ◽  
Ivan A. Klement ◽  
Alessandra Gorgulho ◽  
David McArthur ◽  
...  
Keyword(s):  
Radiation Treatment ◽  
Progression Free Survival ◽  
Malignant Progression ◽  
World Health ◽  
Who Grade ◽  
Stereotactic Radiation ◽  
Grade Ii ◽  
Health Organization ◽  
Grade Iii

Object The authors analyzed the results of stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) for the treatment of recurrent meningiomas that were described at initial resection as showing aggressive, atypical, or malignant features (nonbenign). Methods Twenty-five patients who underwent SRS and/or SRT for nonbenign meningiomas between December 1992 and August 2004 were included. Thirteen of these patients underwent treatment for multiple primary or recurrent lesions. In all, 52 tumors were treated. All histological sections were reviewed and reclassified according to World Health Organization (WHO) 2000 guidelines as benign (Grade I), atypical (Grade II), or anaplastic (Grade III) meningiomas. The median follow-up period was 42 months. Seventeen (68%) of the cases were reclassified as follows: WHO Grade I (five cases), Grade II (11 cases), and Grade III (one case). Malignant progression occurred in eight cases (32%) during the follow-up period; these cases were considered as a separate group. The 3-year progression-free survival (PFS) rates for the Grades I, II, and III, and malignant progression groups were 100, 83, 0, and 11%, respectively (p < 0.001). In the Grade II group, the 3-year PFS rates for patients treated with SRS and SRT were 100 and 33%, respectively (p = 0.1). After initial treatment, 22 new tumors required treatment using SRS or SRT; 17 (77%) of them occurred inside the original resection cavity. Symptomatic edema developed in one patient (4%). Conclusions Stereotactic radiation treatment provided effective local control of “aggressive” Grade I and Grade II meningiomas, whereas Grade III lesions were associated with poor outcome. The outcome of cases in the malignant progression group was intermediate between that of the Grade II and Grade III groups, with the lesions showing a tendency toward malignancy.

scholarly journals Poor Prognostic Factors for Surgical Treatment of Spinal Intramedullary Ependymoma (World Health Organization Grade II)

2020 ◽  
Vol 14 (6) ◽  
pp. 821-828
Author(s):  
Osahiko Tsuji ◽  
Narihito Nagoshi ◽  
Ryota Ishii ◽  
Satoshi Nori ◽  
Satoshi Suzuki ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Prognostic Factors ◽  
World Health Organization ◽  
Scale Score ◽  
Multiple Logistic Regression Analysis ◽  
World Health ◽  
Total Resection ◽  
Grade Ii ◽  
Health Organization

Study Design: Single-center retrospective study.Purpose: We aimed to explore the postoperative prognostic factors for spinal intramedullary ependymoma.Overview of Literature: Ependymoma (World Health Organization grade II) is the most frequent intramedullary spinal tumor and is treated by total resection. However, postoperative deterioration of motor function occasionally occurs.Methods: Eighty patients who underwent surgical resection at Keio University and Fujita Health University in Tokyo, Japan between 2003 and 2015 with more than 2 years of follow-up were enrolled. A good surgical result was defined as an improvement in the modified McCormick Scale score by one grade or more or having the same clinical grade as was observed preoperatively. Meanwhile, a poor result was defined as a reduction in the McCormick Scale score of one grade or more or remaining in grade IV or V at final follow-up. Univariate and multivariate logistic regression analyses of the following factors were performed in the two groups: sex, age, preoperative Visual Analog Scale (VAS), tumor location, the extent of tumor resection, hemosiderin caps, cavity length, and tumor length on magnetic resonance imaging.Results: At final follow-up, 15 patients were included in the poor results group and 65 in the good results group. In the univariate analysis, the factors related to poor results were as follows: higher age, preoperative McCormick Scale score severity, higher preoperative VAS, thoracic location, hemosiderin capped, and non-gross total resection (GTR). A multiple logistic regression analysis was conducted and showed that age, worse preoperative McCormick Scale score, and non-GTR were significant factors for poor prognosis.Conclusions: The independent risk factors for motor deterioration after ependymoma resection were age, worse preoperative McCormick Scale score, and non-GTR. Early surgery for patients with even mild neurological disorders could facilitate functional outcomes. These results may contribute to determining the optimal timing of surgery for spinal intramedullary ependymoma.

scholarly journals Seizure response to temozolomide chemotherapy in patients with WHO grade II oligodendroglioma: a single-institution descriptive study

2018 ◽  
Vol 6 (3) ◽  
pp. 203-208 ◽  
Author(s):  
Aya Haggiagi ◽  
Edward K Avila
Keyword(s):  
Disease Progression ◽  
Seizure Frequency ◽  
World Health ◽  
Low Grade ◽  
Inclusion Criteria ◽  
Who Grade ◽  
Seizure Reduction ◽  
Grade Ii ◽  
Health Organization

Abstract Background Tumor-related epilepsy (TRE) is common in patients with low-grade oligodendrogliomas. TRE is difficult to control despite multiple antiepileptic drugs (AEDs) in up to 30% of patients. Chemotherapy has been used for treatment to avoid potential radiotherapy-related neurotoxicity. This study evaluates the effect of temozolomide on seizure frequency in a homogeneous group with World Health Organization (WHO) grade II oligodendrogliomas. Methods A retrospective analysis was conducted of adult patients with WHO grade II oligodendrogliomas and TRE followed at Memorial Sloan Kettering between 2005 and 2015 who were treated with temozolomide alone either as initial treatment or for disease progression. All had seizures 3 months prior to starting temozolomide. Seizure frequency was reviewed every 2 cycles and at the end of temozolomide treatment. Seizure reduction of ≥50% compared to baseline was defined as improvement. Results Thirty-nine individuals met inclusion criteria. Median follow-up since starting temozolomide was 6 years (0.8-13 years). Reduction in seizure frequency occurred in 35 patients (89.7%). Improvement was independent of AED regimen adjustments or prior antitumor treatment in 16 (41%); of these, AED dosage was successfully reduced or completely eliminated in 10 (25.6%). Twenty-five patients (64.1%) remained on a stable AED regimen. The majority (n = 32, 82%) had radiographically stable disease, 5 (12.8%) had objective radiographic response, and 2 (5.2%) had disease progression. Conclusions Temozolomide may result in reduced seizure frequency, and permit discontinuation of AEDs in patients with WHO II oligodendroglioma. Improvement was observed irrespective of objective tumor response on MRI, emphasizing the importance of incorporating seizure control in assessing response to tumor-directed therapy.

VOLUMETRIC FOLLOW-UP OF MENINGIOMAS

Neurosurgery ◽  
2007 ◽  
Vol 61 (2) ◽  
pp. 281-287 ◽  
Author(s):  
Guenther C. Feigl ◽  
Madjid Samii ◽  
Gerhard A. Horstmann
Keyword(s):  
Tumor Volume ◽  
Treatment Options ◽  
Gamma Knife Radiosurgery ◽  
Local Tumor Control ◽  
World Health ◽  
Tumor Control ◽  
Accurate Analysis ◽  
Standardized Protocol ◽  
Health Organization

Abstract OBJECTIVE The most important treatment options for meningiomas are microsurgery, radiotherapy, and gamma knife radiosurgery (GKRS). The efficacy of GKRS in terms of local tumor control and tumor volume (TV) reduction can best be determined by accurate analysis of changes in tumor size in pre- and post-GKRS images. In this prospective study, we set the focus on evaluating TV changes and treatment outcome of meningiomas using a quantitative volumetric follow-up protocol after GKRS. METHODS Consecutive patients with World Health Organization Grade I and II meningiomas were included in this study. Most patients underwent a microsurgical TV reduction before being treated with GKRS. Follow-up examinations were performed according to a standardized protocol and included magnetic resonance imaging and quantitative volumetric tumor analyses as well as thorough neurological examinations. RESULTS Complete follow-up data was available for 211 patients (243 tumors) with a mean age of 57.9 years. TVs ranging from 0.1 to 48.3cm3 were treated with GKRS using prescription doses ranging from 10 to 22 Gy. The achieved overall tumor control rate determined with quantitative TV analyses after GKRS was 93.4%; a mean TV reduction of 42.1% was achieved in 74.5% of all treated patients. CONCLUSION Results of this study show that a quantitative volumetric follow-up study of meningiomas is a useful method to demonstrate the efficacy of GKRS for meningiomas. Statistically significant TV reductions with a low rate of side effects can be achieved with GKRS.

scholarly journals Stereotactic radiosurgery of World Health Organization grade II and III intracranial meningiomas

Cancer ◽  
2011 ◽  
Vol 118 (4) ◽  
pp. 1048-1054 ◽  
Author(s):  
Bruce E. Pollock ◽  
Scott L. Stafford ◽  
Michael J. Link ◽  
Yolanda I. Garces ◽  
Robert L. Foote
Keyword(s):  
World Health Organization ◽  
Stereotactic Radiosurgery ◽  
World Health ◽  
Intracranial Meningiomas ◽  
Grade Ii ◽  
Health Organization

RADIOSURGERY AS DEFINITIVE MANAGEMENT OF INTRACRANIAL MENINGIOMAS

Neurosurgery ◽  
2008 ◽  
Vol 62 (1) ◽  
pp. 53-60 ◽  
Author(s):  
Douglas Kondziolka ◽  
David Mathieu ◽  
L. Dade Lunsford ◽  
Juan J. Martin ◽  
Ricky Madhok ◽  
...  
Keyword(s):  
Tumor Growth ◽  
World Health Organization ◽  
Stereotactic Radiosurgery ◽  
Growth Control ◽  
Tumor Grade ◽  
World Health ◽  
Morbidity Rate ◽  
Tumor Control ◽  
Intracranial Meningiomas ◽  
Health Organization

Abstract OBJECTIVE Stereotactic radiosurgery has become an important primary or adjuvant minimally invasive management strategy for patients with intracranial meningiomas with the goals of long-term tumor growth prevention and maintenance of patient neurological function. We evaluated clinical and imaging outcomes of meningiomas stratified by histological tumor grade. METHODS The patient cohort consisted of 972 patients with 1045 intracranial meningiomas managed during an 18-year period. The series included 70% women, 49% of whom had undergone a previous resection and 5% of whom had received previous fractionated radiation therapy. Tumor locations included middle fossa (n = 351), posterior fossa (n = 307), convexity (n = 126), anterior fossa (n = 88), parasagittal region (n = 113), or other (n = 115). RESULTS The overall control rate for patients with benign meningiomas (World Health Organization Grade I) was 93%. In those without previous histological confirmation (n = 482), tumor control was 97%. However, for patients with World Health Organization Grade II and III tumors, tumor control was 50 and 17%, respectively. Delayed resection after radiosurgery was necessary in 51 patients (5%) at a mean of 35 months. After 10 years, Grade 1 tumors were controlled in 91% (n = 53); in those without histology, 95% (n = 22) were controlled. None of the patients developed a radiation-induced tumor. The overall morbidity rate was 7.7%. Symptomatic peritumoral imaging changes developed in 4% of the patients at a mean of 8 months. CONCLUSION Stereotactic radiosurgery provided high rates of tumor growth control or regression in patients with benign meningiomas with low risk. This study confirms the role of radiosurgery as an effective management choice for patients with small to medium-sized symptomatic, newly diagnosed or recurrent meningiomas of the brain.

scholarly journals Chordoid Meningioma: Literature Review

2020 ◽  
Vol 39 (01) ◽  
pp. 012-015
Author(s):  
Carlos Roberto Massella Junior ◽  
Marcus Vinicius de Morais ◽  
Rafael Pontes Figueiredo ◽  
Andrezza Garcia Morales ◽  
Paulo Mácio Porto de Melo
Keyword(s):  
World Health ◽  
Diagnostic Challenge ◽  
Chordoid Meningioma ◽  
Who Grade ◽  
Genetic Studies ◽  
Grade Ii ◽  
Health Organization ◽  
Aggressive Clinical Course ◽  
High Degree ◽  
The Brain

AbstractChordoid meningiomas (CMs) are a rare subgroup of tumors, accounting for ∼ 0.5% of all meningiomas. Chordoid meningioma tumors correspond to World Health Organization (WHO) Grade II lesions and behave aggressively, with an increased likelihood of recurrence. There are few genetic studies about CMs, but we understand that there is deletion at many chromosomal loci. Histologically, CMs are characterized by strands and cords of meningothelial cells arranged in a mucinous stroma. Morphologically, it can mimic other chondroid and myxoid tumors within the brain and its vicinity, thus posing a diagnostic challenge. Chordoid meningiomas have an aggressive clinical course and a propensity to recur compared with classical meningiomas. The goal of the treatment is surgery, with total resection of the tumor; however, due to its high degree of recurrence, radiotherapy is often necessary as an adjuvant treatment.

A comparison of World Health Organization tumor grades at recurrence in patients with non–skull base and skull base meningiomas

2010 ◽  
Vol 112 (5) ◽  
pp. 925-933 ◽  
Author(s):  
Susan L. McGovern ◽  
Kenneth D. Aldape ◽  
Mark F. Munsell ◽  
Anita Mahajan ◽  
Franco DeMonte ◽  
...  
Keyword(s):  
Skull Base ◽  
Labeling Index ◽  
World Health ◽  
Skull Base Tumors ◽  
Who Grade ◽  
Grade Ii ◽  
Health Organization ◽  
Skull Base Meningiomas ◽  
Mib 1

Object Despite a favorable outcome for most patients with WHO Grade I meningiomas, a subset of these patients will have recurrent or progressive disease that advances to a higher grade and requires increasingly aggressive therapy. The goal of this study was to identify clinical characteristics associated with the recurrence of benign meningiomas and their acceleration to atypical and malignant histological types. Methods Records of 216 patients with WHO Grade I, II, or III meningioma that were initially treated between 1965 and 2001 were retrospectively reviewed. Median follow-up was 7.2 years. Results Patients with non–skull base cranial meningiomas (82 of 105 [78%]) were more likely to have undergone a gross-total resection than patients with skull base meningiomas (32 of 78 [41%]; p < 0.001). Consequently, patients with Grade I non–skull base cranial meningiomas had better 5-year recurrence-free survival (69%) than patients with Grade I skull base meningiomas (56%) or Grade II or III tumors at any site (50%; p = 0.005). Unexpectedly, patients with non–skull base tumors who experienced a recurrence (8 of 22 [36%]) were more likely than patients with skull base tumors (1 of 19 [5%]) to have a higher grade tumor at recurrence (p = 0.024). Furthermore, the median MIB-1 labeling index of Grade I non–skull base cranial meningiomas (2.60%) was significantly higher than that of Grade I skull base tumors (1.35%; p = 0.016). Conclusions Cranial meningiomas that occur outside of the skull base are more likely to have a higher MIB-1 labeling index and recur with a higher grade than those within the skull base, suggesting that non–skull base cranial tumors may have a more aggressive biology than skull base tumors.

Sign in / Sign up

Export Citation Format

Share Document